Liver Fibrosis - Pipeline Review, H1 2017

Publisher Name :
Date: 11-Apr-2017
No. of pages: 200
Inquire Before Buying

Liver Fibrosis - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Fibrosis - Pipeline Review, H1 2017, provides an overview of the Liver Fibrosis (Gastrointestinal) pipeline landscape.

Liver fibrosis is a scarring process which results in inflammation and liver cell death. Symptoms include abdominal pain, easy bruising, lack of appetite, nausea, tenderness and enlargement of the liver, weight loss and yellowing of skin and eyes. Risk factors include age, heavy alcohol consumption, and chronic infection with hepatitis B or C virus and weakened immune system.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Fibrosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Liver Fibrosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Fibrosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 5, 4, 1, 1, 46 and 11 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 8 molecules, respectively.

Liver Fibrosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Fibrosis (Gastrointestinal).

- The pipeline guide reviews pipeline therapeutics for Liver Fibrosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Liver Fibrosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Liver Fibrosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Liver Fibrosis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Liver Fibrosis (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Liver Fibrosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Liver Fibrosis - Pipeline Review, H1 2017

Table of Contents
Table of Contents 2
Introduction 5
Liver Fibrosis - Overview 6
Liver Fibrosis - Therapeutics Development 7
Liver Fibrosis - Therapeutics Assessment 18
Liver Fibrosis - Companies Involved in Therapeutics Development 30
Liver Fibrosis - Drug Profiles 53
Liver Fibrosis - Dormant Projects 177
Liver Fibrosis - Discontinued Products 180
Liver Fibrosis - Product Development Milestones 181
Appendix 191

List of Tables
Number of Products under Development for Liver Fibrosis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Liver Fibrosis - Pipeline by AdAlta Ltd, H1 2017
Liver Fibrosis - Pipeline by Advinus Therapeutics Ltd, H1 2017
Liver Fibrosis - Pipeline by Allergan Plc, H1 2017
Liver Fibrosis - Pipeline by Angion Biomedica Corp, H1 2017
Liver Fibrosis - Pipeline by Asubio Pharma Co Ltd, H1 2017
Liver Fibrosis - Pipeline by aTyr Pharma Inc, H1 2017
Liver Fibrosis - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H1 2017
Liver Fibrosis - Pipeline by BioLineRx Ltd, H1 2017
Liver Fibrosis - Pipeline by Bioneer Corp, H1 2017
Liver Fibrosis - Pipeline by BiOrion Technologies BV, H1 2017
Liver Fibrosis - Pipeline by Bird Rock Bio Inc, H1 2017
Liver Fibrosis - Pipeline by Cellmid Ltd, H1 2017
Liver Fibrosis - Pipeline by ContraVir Pharmaceuticals Inc, H1 2017
Liver Fibrosis - Pipeline by Dicerna Pharmaceuticals Inc, H1 2017
Liver Fibrosis - Pipeline by Dr. Falk Pharma GmbH, H1 2017
Liver Fibrosis - Pipeline by Dynavax Technologies Corp, H1 2017
Liver Fibrosis - Pipeline by Evotec AG, H1 2017
Liver Fibrosis - Pipeline by Galectin Therapeutics Inc, H1 2017
Liver Fibrosis - Pipeline by Genfit SA, H1 2017
Liver Fibrosis - Pipeline by GenKyoTex SA, H1 2017
Liver Fibrosis - Pipeline by GNI Group Ltd, H1 2017
Liver Fibrosis - Pipeline by HanAll Biopharma Co Ltd, H1 2017
Liver Fibrosis - Pipeline by HEC Pharm Co Ltd, H1 2017
Liver Fibrosis - Pipeline by Immuron Ltd, H1 2017
Liver Fibrosis - Pipeline by Intercept Pharmaceuticals Inc, H1 2017
Liver Fibrosis - Pipeline by INVENT Pharmaceuticals Inc, H1 2017
Liver Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1 2017
Liver Fibrosis - Pipeline by KineMed Inc, H1 2017
Liver Fibrosis - Pipeline by Nitto Denko Corp, H1 2017
Liver Fibrosis - Pipeline by Pfizer Inc, H1 2017
Liver Fibrosis - Pipeline by Pharmaxis Ltd, H1 2017
Liver Fibrosis - Pipeline by Promedior Inc, H1 2017
Liver Fibrosis - Pipeline by Promethera Biosciences SA, H1 2017
Liver Fibrosis - Pipeline by ProMetic Life Sciences Inc, H1 2017
Liver Fibrosis - Pipeline by Ribomic Inc, H1 2017
Liver Fibrosis - Pipeline by RXi Pharmaceuticals Corp, H1 2017
Liver Fibrosis - Pipeline by Samumed LLC, H1 2017
Liver Fibrosis - Pipeline by Silence Therapeutics Plc, H1 2017
Liver Fibrosis - Pipeline by Sirnaomics Inc, H1 2017
Liver Fibrosis - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H1 2017
Liver Fibrosis - Pipeline by TCM Biotech International Corp, H1 2017
Liver Fibrosis - Pipeline by TRACON Pharmaceuticals Inc, H1 2017
Liver Fibrosis - Pipeline by Vascular Biogenics Ltd, H1 2017
Liver Fibrosis - Pipeline by Virobay Inc, H1 2017
Liver Fibrosis - Pipeline by XTuit Pharmaceuticals Inc, H1 2017
Liver Fibrosis - Dormant Projects, H1 2017
Liver Fibrosis - Dormant Projects, H1 2017 (Contd..1), H1 2017
Liver Fibrosis - Dormant Projects, H1 2017 (Contd..2), H1 2017
Liver Fibrosis - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Liver Fibrosis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies [...]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new [...]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating [...]
  • Asia Pacific Makeup Market To Grow Owing To Impactful Promotion And Progress Of Distribution Networks
    The Asia Pacific makeup market is one of the most assorted and active markets in the cosmetics industry throughout the world and is projected to grow at a CAGR of 7.1% between 2013 and 2019. The makeup market in Asia Pacific is assessed to be worth US$22.31 billion by 2019. The world-wide market was at an approximation of US$14.76 [...]
  • Growing Demand in Emergent Markets To Boost Bakery Ingredients Market
    The baking ingredients market is predictable to grow at a CAGR of 5.2% from 2015 to reach an estimated value of US$ 15.19 billion by 2020. Evolving economies throughout the globe have been displaying demand for bakery ingredients at a greater rate in agreement with the economic growth. Numerous companies have been occupied on refining [...]
  • Global Hypercalcemia Treatment Market 2017-2021
    Published: 19-Apr-2017        Price: US 3500 Onwards        Pages: 70
    ABSTRACT About Hypercalcemia Treatment Hypercalcemia is a condition in which the calcium level in the blood is above normal. Too much calcium in the blood can weaken the bones, create stones in the kidneys, and interfere with the functioning of the heart and the brain. Hypercalcemia refers to the condition where too much calcium enters the extracellular fluid or when there is insufficient calcium excretion from the kidneys. The cases of hypercalcemia are mainly caused by ma......
  • Friedreich Ataxia - Pipeline Review, H1 2017
    Published: 11-Apr-2017        Price: US 2000 Onwards        Pages: 85
    Friedreich Ataxia - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Friedreich Ataxia - Pipeline Review, H1 2017, provides an overview of the Friedreich Ataxia (Central Nervous System) pipeline landscape. Friedreich's ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed dow......
  • Fragile X Syndrome - Pipeline Review, H1 2017
    Published: 11-Apr-2017        Price: US 2000 Onwards        Pages: 108
    Fragile X Syndrome - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fragile X Syndrome - Pipeline Review, H1 2017, provides an overview of the Fragile X Syndrome (Genetic Disorders) pipeline landscape. Gastric ulcer is a painful sore or ulcer in the lining of stomach. The most common cause of gastric ulcer is Helicobacter pylori bacterial infection. Symptoms include pain, bloating, re......
  • Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021
    Published: 05-Apr-2017        Price: US 3500 Onwards        Pages: 70
    HCM is the enlargement of the heart muscle (myocardium), which disrupts the functions of the heart. HCM is mostly caused due to gene mutation and is a significant cause of sudden cardiac death in any age group. Hypertrophy is defined as an enlargement of a tissue or organ, and cardiomyopathy refers to diseases related to heart muscles. Therefore, HCM is defined as a condition, which is characterized by abnormal thickening of heart muscles, which makes pumping of blood from the heart to variou......
  • Sarcopenia - Epidemiology Forecast To 2023
    Published: 01-Apr-2017        Price: US 2750 Onwards        Pages: 51
    DelveInsight's "Sarcopenia - Epidemiology Forecast To 2023" Report provides an overview of the epidemiology trends of Sarcopenia in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes historical and forecasted epidemiological data for the prevalent cases of Sarcopenia from 2013-2023. Sarcopenia is the progressive loss of skeletal muscle that comes with aging. Sarcopenia is multifactorial in cause. Most people begin to lose modest amounts of muscle mass after......
  • Natural Killer Cells Therapies- Competitive Landscape,Technology and Pipeline Analysis, 2017
    Published: 01-Apr-2017        Price: US 2450 Onwards        Pages: 207
    DelveInsight's report, "Natural Killer Cells Therapies- Competitive Landscape, Technology and Pipeline Analysis, 2017", emphasizes on the currently active NK cell therapy products and NK cell augmenters in research and development. The report covers 20+ companies, which are active in this field with 40+ products and many different technologies. This report covers NK cell based therapies and drugs that augment (enhance or activate) the NK cells. The report provides in-depth analysis on t......
  • Sarcopenia - Market Insights, Epidemiology and Market Forecast -2023-7 MM
    Published: 01-Apr-2017        Price: US 4950 Onwards        Pages: 51
    DelveInsight's "Sarcopenia - Market Insights, Epidemiology and Market Forecast-2023-7 MM" Report provides an overview of the disease and global market size of the Sarcopenia for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the prevalent cases of Sarcopenia from 2013-2023. Sarcopenia is the progressive loss of skeletal muscle that comes with aging. Sarcopenia is multifactorial in cause. Most peopl......
  • Acromegaly and Gigantism- Epidemiology Forecast To 2023
    Published: 01-Apr-2017        Price: US 2750 Onwards        Pages: 51
    DelveInsight's"Acromegaly and Gigantism- Epidemiology Forecast to 2023" Report provides an overview of the epidemiology trends of Acromegaly in seven major markets (US, France, Germany, Italy, Spain, UK and Japan) and Gigantism in six major markets (US, United Kingdom, France, Germany, Italy and Spain). It includes 10 years epidemiology historical and forecasted data of prevalent cases of Acromegaly and Gigantism by age, sex and sub populations. The Report also discusses the prevailing risk fact......
  • Achondroplasia - Pipeline Review, H1 2017
    Published: 31-Mar-2017        Price: US 2000 Onwards        Pages: 35
    Achondroplasia - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Achondroplasia - Pipeline Review, H1 2017, provides an overview of the Achondroplasia (Musculoskeletal Disorders) pipeline landscape. Achondroplasia is a bone growth disorder that causes disproportionate dwarfism. This is caused by mutations in the FGFR3 gene. Symptoms include decreased muscle tone, apnea, hydrocephalus, ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs